Janney Montgomery Scott LLC Acquires 33,951 Shares of Zevra Therapeutics, Inc. $ZVRA

Janney Montgomery Scott LLC lifted its holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 16.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 236,834 shares of the company’s stock after buying an additional 33,951 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Zevra Therapeutics were worth $2,207,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Gunpowder Capital Management LLC dba Oliver Wealth Management bought a new stake in Zevra Therapeutics during the fourth quarter worth about $53,000. Russell Investments Group Ltd. grew its holdings in Zevra Therapeutics by 235.7% in the third quarter. Russell Investments Group Ltd. now owns 6,374 shares of the company’s stock worth $61,000 after purchasing an additional 4,475 shares during the period. Tower Research Capital LLC TRC increased its stake in shares of Zevra Therapeutics by 617.5% during the second quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock valued at $88,000 after purchasing an additional 8,552 shares in the last quarter. Creative Planning bought a new position in shares of Zevra Therapeutics during the second quarter valued at approximately $92,000. Finally, Qube Research & Technologies Ltd purchased a new position in shares of Zevra Therapeutics during the second quarter valued at approximately $99,000. 35.03% of the stock is currently owned by institutional investors.

Zevra Therapeutics Price Performance

ZVRA stock opened at $14.75 on Thursday. Zevra Therapeutics, Inc. has a 1 year low of $7.16 and a 1 year high of $15.04. The company has a market cap of $872.02 million, a P/E ratio of 7.41 and a beta of 0.85. The stock’s fifty day moving average price is $11.95 and its 200-day moving average price is $10.15.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.18 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.12. Zevra Therapeutics had a return on equity of 51.49% and a net margin of 101.58%.The company had revenue of $36.22 million during the quarter, compared to analysts’ expectations of $31.96 million. As a group, analysts expect that Zevra Therapeutics, Inc. will post 0.56 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ZVRA has been the topic of a number of analyst reports. Citigroup reissued an “outperform” rating on shares of Zevra Therapeutics in a research report on Tuesday, June 9th. Cantor Fitzgerald lifted their price objective on Zevra Therapeutics from $24.00 to $34.00 and gave the company an “overweight” rating in a research note on Monday, June 8th. Weiss Ratings downgraded Zevra Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a report on Friday, May 22nd. Maxim Group increased their target price on Zevra Therapeutics from $25.00 to $35.00 and gave the stock a “buy” rating in a research note on Wednesday, June 10th. Finally, BTIG Research restated a “buy” rating and set a $27.00 price target (up from $23.00) on shares of Zevra Therapeutics in a report on Tuesday, June 9th. Nine investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $29.29.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.